Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$33.67 USD
-0.94 (-2.72%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $33.63 -0.04 (-0.12%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SYRE 33.67 -0.94(-2.72%)
Will SYRE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Updated Share Structure
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics Expands Portfolio and Strengthens Leadership